148 related articles for article (PubMed ID: 38082206)
1. The risk factors for uveitis among psoriatic arthritis patients: a population-based cohort study.
Hijazi N; Gazitt T; Haddad A; Elias M; Kassem S; Feldhamer I; Cohen AD; Sar S; Tomkins-Netzer O; Saliba W; Zisman D
Clin Rheumatol; 2024 Mar; 43(3):1053-1061. PubMed ID: 38082206
[TBL] [Abstract][Full Text] [Related]
2. Treatment persistence of biologics among patients with psoriatic arthritis.
Haddad A; Gazitt T; Feldhamer I; Feld J; Cohen AD; Lavi I; Tatour F; Bergman I; Zisman D
Arthritis Res Ther; 2021 Jan; 23(1):44. PubMed ID: 33514410
[TBL] [Abstract][Full Text] [Related]
3. Uveitis in psoriatic arthritis: study of 406 patients in a single university center and literature review.
De Vicente Delmás A; Sanchez-Bilbao L; Calvo-Río V; Martínez-López D; Herrero-Morant A; Galíndez-Agirregoikoa E; Gonzalez-Mazon I; Barroso-García N; Palmou-Fontana N; Gonzalez-Gay MA; Hernández JL; Blanco R
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36635002
[TBL] [Abstract][Full Text] [Related]
4. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.
Acosta Felquer ML; LoGiudice L; Galimberti ML; Rosa J; Mazzuoccolo L; Soriano ER
Ann Rheum Dis; 2022 Jan; 81(1):74-79. PubMed ID: 34281904
[TBL] [Abstract][Full Text] [Related]
5. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis.
Gisondi P; Bellinato F; Targher G; Idolazzi L; Girolomoni G
Ann Rheum Dis; 2022 Jan; 81(1):68-73. PubMed ID: 34144965
[TBL] [Abstract][Full Text] [Related]
6. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and clinical characteristics of psoriatic arthritis-related uveitis in Madrid, Spain.
Aguado Casanova V; Ventas B; Arroyo Palomo J; Huelin Alcubierre FJ; Villalobos Sánchez L; Revenga Martínez M; Gonzalez-Lopez JJ
Int Ophthalmol; 2023 Mar; 43(3):771-777. PubMed ID: 36040549
[TBL] [Abstract][Full Text] [Related]
8. The association between psoriatic arthritis and venous thromboembolism: a population-based cohort study.
Gazitt T; Pesachov J; Lavi I; Elias M; Haddad A; Feldhamer I; Cohen AD; Saliba W; Zisman D
Arthritis Res Ther; 2022 Jan; 24(1):16. PubMed ID: 34996505
[TBL] [Abstract][Full Text] [Related]
9. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
[TBL] [Abstract][Full Text] [Related]
10. Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System.
Penso L; Bergqvist C; Meyer A; Herlemont P; Weill A; Zureik M; Dray-Spira R; Sbidian E
Arthritis Rheumatol; 2022 Feb; 74(2):244-252. PubMed ID: 34279061
[TBL] [Abstract][Full Text] [Related]
11. Economic impact of biologic utilization patterns in patients with psoriatic arthritis.
Schwartzman S; Li Y; Zhou H; Palmer JB
Clin Rheumatol; 2017 Jul; 36(7):1579-1588. PubMed ID: 28474139
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
Favalli EG; Becciolini A; Carletto A; Conti F; Amato G; Fusaro E; Quartuccio L; Egan CG; Lo Monaco A; Benucci M; Salaffi F; Semeraro A; Parisi S; Ceccarelli F; Piazza I; Foti R
Rheumatol Int; 2020 Feb; 40(2):263-272. PubMed ID: 31435754
[TBL] [Abstract][Full Text] [Related]
13. Clinical features and predictive factors in psoriatic arthritis-related uveitis.
Queiro R; Torre JC; Belzunegui J; González C; De Dios JR; Unanue F; Figueroa M
Semin Arthritis Rheum; 2002 Feb; 31(4):264-70. PubMed ID: 11836659
[TBL] [Abstract][Full Text] [Related]
14. The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study.
Eder L; Haddad A; Rosen CF; Lee KA; Chandran V; Cook R; Gladman DD
Arthritis Rheumatol; 2016 Apr; 68(4):915-23. PubMed ID: 26555117
[TBL] [Abstract][Full Text] [Related]
15. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis and Psoriatic Arthritis-Related Uveitis: Different Ophthalmological Manifestations and Ocular Inflammation Features.
Abbouda A; Abicca I; Fabiani C; Scappatura N; Peña-García P; Scrivo R; Priori R; Paroli MP
Semin Ophthalmol; 2017; 32(6):715-720. PubMed ID: 27419848
[TBL] [Abstract][Full Text] [Related]
17. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
[TBL] [Abstract][Full Text] [Related]
18. The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database.
Vasilakis-Scaramozza C; Persson R; Hagberg KW; Jick S
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1755-1763. PubMed ID: 31981426
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and Medication Pattern Change of Psoriatic Diseases in Taiwan from 2000 to 2013: A Nationwide, Population-based Cohort Study.
Wei JC; Shi LH; Huang JY; Wu XF; Wu R; Chiou JY
J Rheumatol; 2018 Mar; 45(3):385-392. PubMed ID: 29335350
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
[No Abstract] [Full Text] [Related]
[Next] [New Search]
